AVELUMAB

Information current as at:

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Bavencio®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: Merck Healthcare Pty Ltd
Condition/indication: (therapeutic use): Renal cell carcinoma (RCC)
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: Change to listing (Minor Submission)
Comment:: --
Other PBAC consideration:: AVELUMAB

Progress Details

Submission received for:: March 2021 PBAC meeting
Opportunity for consumer comment:: Open 23/12/2020 and close 10/02/2021 (see PBS Website)
PBAC meeting:: Held on 10/03/2021
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:: Has not yet commenced
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

Glossary

PBAC Outcome

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

PBAC Public Summary Documents – March 2021

Case ID

a281

Page last updated

31 March 2026

Return to the Medicine Status Listing

v.9.19